The ACC/AHA published new guidelines for managing acute PE on February 19, 2026. Today I'm joined by Dr. Scott Woller, MD, MACP, FCCP, who was co-chair of the American College of Chest Physicians Clinical Practice Guideline for antithrombotic therapy for venous thromboembolism, last updated in 2021. He also served as co-chair for the peer review committee for these new guidelines, and has lots of great insights into how to use them in clinical practice and research. 

2026 ACC/AHA Guidelines for Diagnosis and Managing Acute PE

Some highlights from the guidelines:

  • New categories of PE: 
    • A: asymptomatic
    • B: symptomatic, low risk
    • C: symptomatic, high risk
    • D: incipient shock
    • E: cardiogenic shock
  • PE response teams (PERTs) are ascendant
  • Use enoxaparin instead of heparin drip!
  • Advanced therapies for category D and E
  • Half dose DOACs for extended treatment
  • Shared decision making for clots provoked by minor risk factors
  • Patients with persistent symptoms need evaluation for CTEPD


Music from Uppbeat (free for Creators!):

https://uppbeat.io/t/soundroll/dope

License code: NP8HLP5WKGKXFW2R

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Stephen Jenkins, MD, Austin Rupp, MD. Innehållet i podden är skapat av Stephen Jenkins, MD, Austin Rupp, MD och inte av, eller tillsammans med, Poddtoppen.